Exact Sciences
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The last earnings update was 20 days ago. More info.
Add to Portfolio Compare Print
EXAS Share Price and Events
7 Day Returns
1 Year Returns
EXAS Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Exact Sciences (EXAS) | 7.5% | 4.3% | 12.4% | 84% | 1605.5% | 608.8% |
| US Biotechs | -1.6% | -5.5% | -6.5% | -5.5% | 9.7% | 12% |
| US Market | -0.7% | -2% | 2.4% | 3% | 39.2% | 42% |
1 Year Return vs Industry and Market
- EXAS outperformed the Biotechs industry which returned -5.5% over the past year.
- EXAS outperformed the Market in United States of America which returned 3% over the past year.
Value
Is Exact Sciences undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
Exact Sciences
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for Exact Sciences.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 13 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 10.5% |
| Perpetual Growth Rate | 10-Year US Government Bond Rate | 2.7% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year US Govt Bond Rate | 2.7% |
| Equity Risk Premium | S&P Global | 6% |
| Biotechs Unlevered Beta | Simply Wall St/ S&P Global | 1.38 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.379 (1 + (1- 21%) (6.56%)) |
1.302 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
1.3 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.302 * 5.96%) |
10.49% |
Discounted Cash Flow Calculation for NasdaqCM:EXAS using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for Exact Sciences is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
| Levered FCF (USD, Millions) | Source |
Present Value Discounted (@ 10.49%) |
|
|---|---|---|---|
| 2019 | -366.58 | Analyst x2 | -331.78 |
| 2020 | -88.57 | Analyst x2 | -72.55 |
| 2021 | 156.61 | Analyst x1 | 116.11 |
| 2022 | 242.55 | Est @ 54.88% | 162.75 |
| 2023 | 337.72 | Est @ 39.23% | 205.10 |
| 2024 | 433.23 | Est @ 28.28% | 238.13 |
| 2025 | 522.55 | Est @ 20.62% | 259.95 |
| 2026 | 602.24 | Est @ 15.25% | 271.16 |
| 2027 | 671.47 | Est @ 11.49% | 273.62 |
| 2028 | 731.00 | Est @ 8.87% | 269.60 |
| Present value of next 10 years cash flows | $1,392.08 | ||
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2028
× (1 + g) ÷ (Discount Rate – g)
= $731.00 × (1 + 2.73%) ÷ (10.49% – 2.73%) |
$9,678.37 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)10
= $9,678.37 ÷ (1 + 10.49%)10 |
$3,569.51 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 10 years cash flows +
Terminal Value
= $1,392.08 + $3,569.51 |
$4,961.59 |
| Equity Value per Share (USD) |
= Total value / Shares Outstanding
= $4,961.59 / 129.14 |
$38.42 |
| Calculation | Result | |
|---|---|---|
| Value per share (USD) | From above. | $38.42 |
| Current discount | Discount to share price of
$96.19
= -1 x ($96.19 - $38.42) / $38.42 |
-150.4% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
- The current share price of Exact Sciences is above its future cash flow value.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Exact Sciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Exact Sciences's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2019-03-31) in USD | $-1.77 |
| NasdaqCM:EXAS Share Price ** | NasdaqCM (2019-05-17) in USD | $96.19 |
| United States of America Biotechs Industry PE Ratio | Median Figure of 34 Publicly-Listed Biotechs Companies | 19.48x |
| United States of America Market PE Ratio | Median Figure of 3,088 Publicly-Listed Companies | 17.89x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Exact Sciences.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = NasdaqCM:EXAS Share Price ÷ EPS (both in USD) = 96.19 ÷ -1.77 |
-54.3x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Exact Sciences is loss making, we can't compare its value to the US Biotechs industry average.
- Exact Sciences is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does
Exact Sciences's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -54.3x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 13 Analysts |
72.1%per year |
| United States of America Biotechs Industry PEG Ratio | Median Figure of 27 Publicly-Listed Biotechs Companies | 1.32x |
| United States of America Market PEG Ratio | Median Figure of 2,117 Publicly-Listed Companies | 1.56x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for Exact Sciences, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Exact Sciences's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2019-03-31) in USD | $6.02 |
| NasdaqCM:EXAS Share Price * | NasdaqCM (2019-05-17) in USD | $96.19 |
| United States of America Biotechs Industry PB Ratio | Median Figure of 416 Publicly-Listed Biotechs Companies | 3.21x |
| United States of America Market PB Ratio | Median Figure of 5,195 Publicly-Listed Companies | 1.83x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = NasdaqCM:EXAS Share Price ÷ Book Value per Share (both in USD) = 96.19 ÷ 6.02 |
15.98x |
* Primary Listing of Exact Sciences.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Exact Sciences is overvalued based on assets compared to the US Biotechs industry average.
Value checks
We assess Exact Sciences's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check) Exact Sciences has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
Future Performance
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Exact Sciences's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
- Exact Sciences's earnings growth is expected to exceed the United States of America market average.
- Exact Sciences's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| NasdaqCM:EXAS Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 13 Analysts | 72.1% |
| NasdaqCM:EXAS Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 13 Analysts | 29.6% |
| United States of America Biotechs Industry Earnings Growth Rate | Market Cap Weighted Average | 22.6% |
| United States of America Biotechs Industry Revenue Growth Rate | Market Cap Weighted Average | 17.5% |
| United States of America Market Earnings Growth Rate | Market Cap Weighted Average | 13.9% |
| United States of America Market Revenue Growth Rate | Market Cap Weighted Average | 7.3% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (1 month ago) | See Below |
| Future Estimates | Average of up to 13 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 2,469 | 343 | 2 | |
| 2022-12-31 | 1,937 | 209 | 3 | |
| 2021-12-31 | 1,513 | 177 | -1 | 8 |
| 2020-12-31 | 1,070 | -51 | -155 | 12 |
| 2019-12-31 | 746 | -177 | -283 | 13 |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2019-03-31 | 526 | -105 | -219 |
| 2018-12-31 | 454 | -69 | -175 |
| 2018-09-30 | 399 | -69 | -143 |
| 2018-06-30 | 353 | -70 | -124 |
| 2018-03-31 | 308 | -77 | -119 |
| 2017-12-31 | 266 | -72 | -114 |
| 2017-09-30 | 214 | -98 | -130 |
| 2017-06-30 | 169 | -118 | -141 |
| 2017-03-31 | 133 | -121 | -155 |
| 2016-12-31 | 99 | -130 | -167 |
| 2016-09-30 | 79 | -133 | -170 |
| 2016-06-30 | 63 | -145 | -175 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (1 month ago) | See Below |
| Future Estimates | Average of up to 13 Analyst Estimates (S&P Global) | See Below |
All data from Exact Sciences Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 2.72 | 2.72 | 2.72 | 1.00 |
| 2022-12-31 | 1.56 | 1.78 | 1.34 | 2.00 |
| 2021-12-31 | 0.12 | 0.25 | -0.10 | 5.00 |
| 2020-12-31 | -1.14 | -0.49 | -1.59 | 9.00 |
| 2019-12-31 | -2.21 | -2.02 | -2.42 | 10.00 |
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2019-03-31 | -1.77 |
| 2018-12-31 | -1.43 |
| 2018-09-30 | -1.18 |
| 2018-06-30 | -1.03 |
| 2018-03-31 | -1.00 |
| 2017-12-31 | -0.99 |
| 2017-09-30 | -1.15 |
| 2017-06-30 | -1.29 |
| 2017-03-31 | -1.46 |
| 2016-12-31 | -1.63 |
| 2016-09-30 | -1.72 |
| 2016-06-30 | -1.81 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if Exact Sciences will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
Future performance checks
We assess Exact Sciences's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Exact Sciences has a total score of 5/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
Past Performance
How has Exact Sciences performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Exact Sciences does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- Unable to compare Exact Sciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare Exact Sciences's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
All data from Exact Sciences Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2019-03-31 | 526.21 | -218.78 | 493.74 | 85.29 |
| 2018-12-31 | 454.46 | -175.15 | 427.74 | 68.21 |
| 2018-09-30 | 398.89 | -142.94 | 368.76 | 59.95 |
| 2018-06-30 | 353.17 | -124.47 | 325.73 | 54.05 |
| 2018-03-31 | 307.92 | -118.88 | 293.07 | 49.07 |
| 2017-12-31 | 265.99 | -114.40 | 262.96 | 42.14 |
| 2017-09-30 | 213.82 | -129.80 | 240.74 | 36.55 |
| 2017-06-30 | 169.37 | -140.71 | 218.81 | 32.45 |
| 2017-03-31 | 132.90 | -154.68 | 205.06 | 31.35 |
| 2016-12-31 | 99.38 | -167.21 | 189.72 | 33.47 |
| 2016-09-30 | 78.56 | -170.03 | 175.53 | 35.76 |
| 2016-06-30 | 63.07 | -175.17 | 167.44 | 37.99 |
| 2016-03-31 | 50.01 | -169.48 | 154.13 | 37.47 |
| 2015-12-31 | 39.44 | -157.80 | 140.09 | 33.91 |
| 2015-09-30 | 26.52 | -150.26 | 127.98 | 29.54 |
| 2015-06-30 | 13.89 | -139.37 | 112.28 | 28.15 |
| 2015-03-31 | 5.77 | -119.74 | 90.40 | 27.21 |
| 2014-12-31 | 1.80 | -100.05 | 69.34 | 28.67 |
| 2014-09-30 | 1.33 | -79.79 | 50.84 | 29.79 |
| 2014-06-30 | 2.37 | -58.89 | 33.33 | 28.30 |
| 2014-03-31 | 3.40 | -51.77 | 27.86 | 27.58 |
| 2013-12-31 | 4.14 | -46.51 | 23.73 | 27.18 |
| 2013-09-30 | 4.14 | -48.32 | 21.28 | 31.40 |
| 2013-06-30 | 4.14 | -50.11 | 19.53 | 34.91 |
| 2013-03-31 | 4.14 | -52.63 | 16.32 | 40.66 |
| 2012-12-31 | 4.14 | -52.42 | 14.66 | 42.13 |
| 2012-09-30 | 4.15 | -48.34 | 13.32 | 39.36 |
| 2012-06-30 | 4.15 | -43.16 | 12.53 | 34.98 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if Exact Sciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- It is difficult to establish if Exact Sciences has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Exact Sciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess Exact Sciences's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Exact Sciences has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
Health
How is Exact Sciences's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Exact Sciences's finances.
The net worth of a company is the difference between its assets and liabilities.
- Exact Sciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Exact Sciences's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- High level of physical assets or inventory.
- Debt is covered by short term assets, assets are 1.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Exact Sciences Company Filings, last reported 1 month ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2019-03-31 | 776.94 | 815.32 | 1,282.71 |
| 2018-12-31 | 680.94 | 688.83 | 1,124.18 |
| 2018-09-30 | 716.73 | 681.32 | 1,185.22 |
| 2018-06-30 | 744.39 | 654.59 | 1,222.16 |
| 2018-03-31 | 687.02 | 492.41 | 1,042.17 |
| 2017-12-31 | 520.42 | 4.45 | 424.72 |
| 2017-09-30 | 527.14 | 6.09 | 462.52 |
| 2017-06-30 | 540.69 | 6.23 | 484.26 |
| 2017-03-31 | 309.52 | 6.37 | 274.67 |
| 2016-12-31 | 335.30 | 4.81 | 311.10 |
| 2016-09-30 | 362.33 | 6.65 | 337.83 |
| 2016-06-30 | 249.39 | 6.78 | 224.08 |
| 2016-03-31 | 288.33 | 6.82 | 262.59 |
| 2015-12-31 | 326.86 | 7.36 | 306.88 |
| 2015-09-30 | 361.29 | 6.16 | 343.51 |
| 2015-06-30 | 224.84 | 6.23 | 210.82 |
| 2015-03-31 | 258.21 | 3.67 | 245.15 |
| 2014-12-31 | 288.98 | 3.76 | 282.76 |
| 2014-09-30 | 215.11 | 1.45 | 211.14 |
| 2014-06-30 | 242.87 | 1.54 | 234.80 |
| 2014-03-31 | 121.76 | 1.63 | 116.01 |
| 2013-12-31 | 135.32 | 1.71 | 133.26 |
| 2013-09-30 | 145.09 | 1.80 | 147.84 |
| 2013-06-30 | 153.58 | 1.88 | 157.73 |
| 2013-03-31 | 89.13 | 1.96 | 95.48 |
| 2012-12-31 | 98.60 | 2.04 | 108.12 |
| 2012-09-30 | 110.66 | 2.15 | 118.57 |
| 2012-06-30 | 64.02 | 1.00 | 70.87 |
- Exact Sciences's level of debt (104.9%) compared to net worth is high (greater than 40%).
- The level of debt compared to net worth has increased over the past 5 years (1.3% vs 104.9% today).
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- Exact Sciences has sufficient cash runway for more than 3 years based on current free cash flow.
- Exact Sciences has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 14.6% each year.
Financial health checks
We assess Exact Sciences's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Exact Sciences has a total score of 4/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
Dividends
What is Exact Sciences's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
$2,000 of
Exact Sciences
shares you are expected to receive
$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Exact Sciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Exact Sciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 13 Analyst Estimates (S&P Global) | See Below |
| Global Biotechs Industry Average Dividend Yield | Market Cap Weighted Average of 19 Stocks | 2.4% |
| United States of America Market Average Dividend Yield | Market Cap Weighted Average of 2000 Stocks | 2.5% |
| United States of America Minimum Threshold Dividend Yield | 10th Percentile | 0.8% |
| United States of America Bottom 25% Dividend Yield | 25th Percentile | 1.4% |
| United States of America Top 25% Dividend Yield | 75th Percentile | 3.7% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-12-31 | ||
| 2022-12-31 | ||
| 2021-12-31 | 0.00 | 2.00 |
| 2020-12-31 | 0.00 | 3.00 |
| 2019-12-31 | 0.00 | 3.00 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Exact Sciences has not reported any payouts.
- Unable to verify if Exact Sciences's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Exact Sciences's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Exact Sciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Exact Sciences has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
Management
CEO
| COMPENSATION | $6,991,997 |
| AGE | 52 |
| TENURE AS CEO | 10.1 years |
CEO Bio
Mr. Kevin T. Conroy serves as Director at ARYA Sciences Acquisition Corp. Mr. Conroy has been the Chief Executive Officer and President at Exact Sciences Corporation since April 2, 2009. Mr. Conroy served as the President and Chief Executive Officer of Third Wave Japan, Inc. He served as the President and Chief Executive Officer of Third Wave Technologies, Inc. from December 15, 2005 to July 2008 and its Secretary from October 27, 2004 to July 2008. He also served as General Counsel of Third Wave Technologies, Inc. from his joining in October 27, 2004 to December 2005 and also served as its Vice President of Legal Affairs since July 2004. Prior to joining Third Wave, Mr. Conroy served as Intellectual Property Counsel at GE Healthcare and oversaw the development and management of its Information Technologies group intellectual property portfolio and developed and executed litigation, licensing and corporate and product acquisition legal strategies. Before joining GE, he served as Chief Operating Officer of two early stage venture-based technology companies in Northern California. Prior to those positions, he was an Intellectual Property litigator at two Chicago law firms, McDermott Will & Emery and Pattishall, McAuliffe, Newbury, Hilliard and Geraldson, where he was a Partner. He has been the Chairman of the Board and a Director of EXACT Sciences Corporation since March 21, 2014 and March 18, 2009 respectively. He has been a Director of Epizyme, Inc. since February 27, 2017. He served as a Director of Third Wave Technologies, Inc., since December 15, 2005 Mr. Conroy holds a Bachelor of Science in Electrical Engineering at Michigan State University and his Law Degree from the University of Michigan. Mr. Kevin T. Conroy serves as Director at ARYA Sciences Acquisition Corp.
CEO Compensation
- Kevin's compensation has been consistent with company performance over the past year.
- Kevin's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the Exact Sciences management team in years:
- The tenure for the Exact Sciences management team is about average.
Management Team
Kevin Conroy
Chairman of the Board
$7M
52
10.1 yrs
Jeff Elliott
Chief Financial Officer
$2M
40
2.5 yrs
Graham Lidgard
Chief Science Officer
$2M
69
9.8 yrs
D. Coward
Chief Administrative Officer
$2M
53
0.8 yrs
Mark Stenhouse
President of Cologuard
$4M
51
1.1 yrs
Ana Hooker
Senior Vice President of Operations
52
4.3 yrs
Gary Frings
Chief Information Officer
4.3 yrs
Megan Jones
Associate Manager of Investor Relations
Tim Caprez
Chief Compliance Counsel & VP
4.3 yrs
Vic Parker
Head of Sales
0.4 yrs
Board of Directors Tenure
Average tenure and age of the Exact Sciences board of directors in years:
- The tenure for the Exact Sciences board of directors is about average.
Board of Directors
Kevin Conroy
Chairman of the Board
$7M
52
5.2 yrs
Kay Napier Zanotti
Independent Director
$270K
63
10.1 yrs
Dave Thompson
Lead Independent Director
$288K
76
5.2 yrs
Dan Levangie
Independent Director
$272K
67
8.8 yrs
Mike Wyzga
Independent Director
$275K
63
4.3 yrs
Tom Carey
Independent Director
$256K
56
6.1 yrs
Jim Doyle
Independent Director
$266K
72
4.8 yrs
John Fallon
Independent Director
$269K
70
3.3 yrs
Eli Casdin
Director
$474K
1.5 yrs
Kathleen Sebelius
Director
70
0.2 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price ($) | Value ($) | |
|---|---|---|---|---|---|---|---|---|---|---|
Management checks
We assess Exact Sciences's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Exact Sciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
News
Simply Wall St News
Investors Who Bought Exact Sciences (NASDAQ:EXAS) Shares Three Years Ago Are Now Up 1647%
See our latest analysis for Exact Sciences Given that Exact Sciences didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. … Despite the strong run, top performers like Exact Sciences have been known to go on winning for decades. … NasdaqCM:EXAS Income Statement, May 17th 2019 Exact Sciences is well known by investors, and plenty of clever analysts have tried to predict the future profit levels.
Simply Wall St - – Full articleWhat Do Analysts Think About Exact Sciences Corporation's (NASDAQ:EXAS) Growth?
In December 2018, Exact Sciences Corporation (NASDAQ:EXAS) announced its latest earnings update, which … company earnings became less negative compared to the previous year's level
Simply Wall St - – Full articleIs Exact Sciences Corporation's (NASDAQ:EXAS) CEO Overpaid Relative To Its Peers?
First, this article will compare CEO compensation with compensation at other large companies. … How Does Kevin Conroy's Compensation Compare With Similar Sized Companies. … At the time of writing our data says that Exact Sciences Corporation has a market cap of US$11b, and is paying total annual CEO compensation of US$13m.
Simply Wall St - – Full articleWhen Can We Expect A Profit From Exact Sciences Corporation (NASDAQ:EXAS)?
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. … The US$12b market-cap company announced a latest loss of -US$175.1m on 31 December 2018 for its most recent financial year result? … View our latest analysis for Exact Sciences
Simply Wall St - – Full articleWhat Investors Should Know About Exact Sciences Corporation's (NASDAQ:EXAS) Financial Strength
Stocks with market capitalization between $2B and $10B, such as Exact Sciences Corporation (NASDAQ:EXAS) with a size of US$8.4b, do not attract as much attention from the investing community as do the small-caps and large-caps. … Today we will look at EXAS’s financial liquidity and debt levels, which are strong indicators for whether the company can weather economic downturns or fund strategic acquisitions for future growth. … Don’t forget that this is a general and concentrated examination of Exact Sciences’s financial health, so you should conduct further analysis.
Simply Wall St - – Full articleIs Exact Sciences Corporation's (NASDAQ:EXAS) CEO Being Overpaid?
This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … Our data indicates that Exact Sciences Corporation is worth US$9.2b, and total annual CEO compensation is US$13m. … Thus we can conclude that Kevin Conroy receives more in total compensation than the median of a group of companies in the same market, and of similar size to Exact Sciences Corporation
Simply Wall St - – Full articleIs Exact Sciences Corporation's (NASDAQ:EXAS) Balance Sheet Strong Enough To Weather A Storm?
Small and large cap stocks are widely popular for a variety of reasons, however, mid-cap companies such as Exact Sciences Corporation (NASDAQ:EXAS), with a market cap of US$6.19b, often get neglected by retail investors. … Despite this, the two other categories have lagged behind the risk-adjusted returns of commonly ignored mid-cap stocks. … View our latest analysis for Exact Sciences
Simply Wall St - – Full articleAre Exact Sciences Corporation's (NASDAQ:EXAS) Interest Costs Too High?
Small and large cap stocks are widely popular for a variety of reasons, however, mid-cap companies such as Exact Sciences Corporation (NASDAQ:EXAS), with a market cap of US$8.50b, often get neglected by retail investors. … Don’t forget that this is a general and concentrated examination of Exact Sciences’s financial health, so you should conduct further analysis. … Check out our latest analysis for Exact Sciences
Simply Wall St - – Full articleOne Thing To Consider Before Buying Exact Sciences Corporation (NASDAQ:EXAS)
Every stock in the market is exposed to this risk, which arises from macroeconomic factors such as economic growth and geo-political tussles just to name a few. … Not every stock is exposed to the same level of market risk. … EXAS's beta implies it may be a stock that investors with high-beta portfolios might find relevant if they wanted to reduce their exposure to market risk, especially during times of downturns.
Simply Wall St - – Full articleWho Are The Major Shareholders Of Exact Sciences Corporation (NASDAQ:EXAS)?
In this article, I'm going to take a look at Exact Sciences Corporation’s (NASDAQ:EXAS) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors. … See our latest analysis for Exact Sciences NasdaqCM:EXAS Ownership_summary May 25th 18 Institutional Ownership Institutions account for 90.57% of EXAS's outstanding shares, a significant enough holding to move stock prices if they start buying and selling in large quantities, especially when there are relatively small amounts of shares available on the market to trade. … General Public Ownership With 7.32% ownership, the general public are also an important ownership class in EXAS.
Simply Wall St - – Full articleCompany Info
Description
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.
Details
| Name: | Exact Sciences Corporation |
| EXAS | |
| Exchange: | NasdaqCM |
| Founded: | 1995 |
| $12,421,859,248 | |
| 129,138,780 | |
| Website: | http://www.exactsciences.com |
| Address: |
Exact Sciences Corporation 441 Charmany Drive, Madison, Wisconsin, 53719, United States |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| NasdaqCM | EXAS | Common Stock | Nasdaq Capital Market | US | USD | 31. Jan 2001 | |
| DB | EXK | Common Stock | Deutsche Boerse AG | DE | EUR | 31. Jan 2001 |
Number of employees
Current staff
Industry
| Biotechnology | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/05/20 01:31 |
| End of day share price update: | 2019/05/17 00:00 |
| Last estimates confirmation: | 2019/05/07 |
| Last earnings filing: | 2019/04/30 |
| Last earnings reported: | 2019/03/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
